provided a comprehensive genomic landscape of BIA-ALCL including JAK/STAT activating mutations and inactivation of epigenetic modifiers, involving lysine methyltransferase 2C (KMT2C), lysine methyltransferase 2D (KMT2D), chromodomain helicase DNA binding protein 2 (CHD2), and CREB binding protein (CREBBP) (31). The gene discussed is KMT2D; the disease is anaplastic large cell lymphoma.